Long-term metformin use reduces gastric cancer risk in type 2 diabetics without insulin treatment: A nationwide cohort study

Alimentary Pharmacology and Therapeutics

Volumn 39, Issue 8, 2014, Pages 854-863

  Kim, Y I ^a   Kim, S Y ^a   Cho, S J ^a   Park, J H ^a   Choi, I J ^a   Lee, Y J ^a   Lee, E K ^a   Kook, M C ^a   Kim, C G ^a   Ryu, K W ^a   Kim, Y W ^a  

^a National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; ORAL ANTIDIABETIC AGENT; PIG INSULIN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; ETHNIC GROUP; FEMALE; HUMAN; KOREAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; STOMACH CANCER; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; STOMACH NEOPLASMS; TIME FACTORS;

EID: 84896404663     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12660     Document Type: Article

References (37)

1. Jalving M, Gietema JA, Lefrandt JD, et al,. Metformin: taking away the candy for cancer Eur J Cancer 2010; 46: 2369-80.
2. McFarland MS, Cripps R,. Diabetes mellitus and increased risk of cancer: focus on metformin and the insulin analogs. Pharmacotherapy 2010; 30: 1159-78.
3. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F,. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122: 253-70.
4. Masur K, Vetter C, Hinz A, et al,. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer 2011; 104: 345-52.
5. Pollak M,. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-28.
6. Ikeda F, Doi Y, Yonemoto K, et al,. Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study. Gastroenterology 2009; 136: 1234-41.
7. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S,. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871-7.
8. Park SM, Lim MK, Shin SA, Yun YH,. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 2006; 24: 5017-24.
9. Tseng CH,. Diabetes conveys a higher risk of gastric cancer mortality despite an age-standardised decreasing trend in the general population in Taiwan. Gut 2011; 60: 774-9.
10. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49: 347-53.
11. Acbay O, Celik AF, Gundogdu S,. Does Helicobacter pylori-induced gastritis enhance food-stimulated insulin release Dig Dis Sci 1996; 41: 1327-31.
12. Gunji T, Matsuhashi N, Sato H, et al,. Helicobacter pylori infection significantly increases insulin resistance in the asymptomatic Japanese population. Helicobacter 2009; 14: 144-50.
13. Ben Sahra I, Laurent K, Loubat A, et al,. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-86.
14. Brown KA, Hunger NI, Docanto M, Simpson ER,. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Res Treat 2010; 123: 591-6.
15. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN,. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) 2008; 1: 369-75.
16. Anisimov VN, Berstein LM, Egormin PA, et al,. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005; 40: 685-93.
17. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E,. Sulphonylureas and cancer: a case-control study. Acta Diabetol 2009; 46: 279-84.
18. Baur DM, Klotsche J, Hamnvik O-PR, et al,. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism 2011; 60: 1363-71.
19. Monami M, Colombi C, Balzi D, et al,. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34: 129-31.
20. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC,. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC cancer 2011; 11: 20.
21. Currie CJ, Poole CD, Gale EA,. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
22. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR,. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010; 33: 1304-8.
23. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-5.
24. Jee SH, Sull JW, Park J, et al,. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355: 779-87.
25. Lee SY, Jung KY, Lee IK, et al,. Prevalence of treated epilepsy in Korea based on national health insurance data. J Korean Med Sci 2012; 27: 285-90.
26. Lee JA, Park JH, Lee EJ, Kim SY, Kim Y, Lee SI,. High-quality, low-cost gastrectomy care at high-volume hospitals: results from a population-based study in South Korea. Arch Surg 2011; 146: 930-6.
27. International classification of diseases and related health problems: manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. 10th ed. Geneva: World Health Organization, 1992.
28. Bornschein J, Rokkas T, Selgrad M, Malfertheiner P,. Gastric cancer: clinical aspects, epidemiology and molecular background. Helicobacter 2011; 16 (Suppl. 1): 45-52.
29. Kirpichnikov D, McFarlane SI, Sowers JR,. Metformin: an update. Ann Intern Med 2002; 137: 25-33.
30. Shackelford DB, Shaw RJ,. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-75.
31. Kim YH, Liang H, Liu X, et al,. AMPKalpha modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer. Cancer Res 2012; 72: 2512-21.
32. Kato K, Gong J, Iwama H, et al,. The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 2012; 11: 549-60.
33. Bowker SL, Majumdar SR, Veugelers P, Johnson JA,. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29: 254-8.
34. Govindarajan R, Ratnasinghe L, Simmons DL, et al,. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-81.
35. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA,. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-72.
36. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G,. Aspirin, salicylates, and cancer. Lancet 2009; 373: 1301-9.
37. Osmak M,. Statins and cancer: current and future prospects. Cancer Lett 2012; 324: 1-12.